Rituximab for the Treatment of Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Autor:	Brett Jepson, Steven R. Ytterberg, Peter A. Merkel, Philip Seo, Eli M. Miloslavsky, David Ikle, Coen A. Stegeman, N. K. Tchao, Carol A. Langford, Paul A. Monach, E W St Clair, Tobias Peikert, Linna Ding, Lisa Viviano, Eugene Y. Kissin, Ulrich Specks, John H. Stone, Nancy B. Allen, C. G. M. Kallenberg, Robert Spiera, Karina A. Keogh, Gary S. Hoffman, Paul Brunetta, Duvuru Geetha, M. Villarreal, Fernando C. Fervenza
Rok vydání:	2014
Předmět:	Cyclophosphamide business.industry Immunology Azathioprine urologic and male genital diseases medicine.disease respiratory tract diseases Rheumatology Maintenance therapy immune system diseases Prednisone Monoclonal medicine Immunology and Allergy Rituximab cardiovascular diseases skin and connective tissue diseases Vasculitis business medicine.drug Anti-neutrophil cytoplasmic antibody
Zdroj:	Arthritis & Rheumatology. 66:3151-3159
ISSN:	2326-5191
DOI:	10.1002/art.38788
Popis:	Introduction Disease relapses are frequent in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). We evaluated the outcomes of patients re-treated with rituximab (RTX) and prednisone for severe disease relapses.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f06b4901a2844cee9d2a23b55950bfb0 https://doi.org/10.1002/art.38788 Zobrazit plný text záznamu Plný text